...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status
【24h】

Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status

机译:按HPV病状分层的N2-N3头颈癌原发放疗后的颞结节消退和区域控制

获取原文
获取原文并翻译 | 示例

摘要

Purpose To compare the temporal lymph node (LN) regression and regional control (RC) after primary chemoradiation therapy/radiation therapy in human papillomavirus-related [HPV(+)] versus human papillomavirus-unrelated [HPV(-)] head-and-neck cancer (HNC). Methods and Materials All cases of N2-N3 HNC treated with radiation therapy/chemoradiation therapy between 2003 and 2009 were reviewed. Human papillomavirus status was ascertained by p16 staining on all available oropharyngeal cancers. Larynx/hypopharynx cancers were considered HPV(-). Initial radiologic complete nodal response (CR) (≤1.0 cm 8-12 weeks after treatment), ultimate LN resolution, and RC were compared between HPV(+) and HPV(-) HNC. Multivariate analysis identified outcome predictors. Results A total of 257 HPV(+) and 236 HPV(-) HNCs were identified. The initial LN size was larger (mean, 2.9 cm vs 2.5 cm; P<.01) with a higher proportion of cystic LNs (38% vs 6%, P<.01) in HPV(+) versus HPV(-) HNC. CR was achieved is 125 HPV(+) HNCs (49%) and 129 HPV(-) HNCs (55%) (P=.18). The mean post treatment largest LN was 36% of the original size in the HPV(+) group and 41% in the HPV(-) group (P<.01). The actuarial LN resolution was similar in the HPV(+) and HPV(-) groups at 12 weeks (42% and 43%, respectively), but it was higher in the HPV(+) group than in the HPV(-) group at 36 weeks (90% vs 77%, P<.01). The median follow-up period was 3.6 years. The 3-year RC rate was higher in the HPV(-) CR cases versus non-CR cases (92% vs 63%, P<.01) but was not different in the HPV(+) CR cases versus non-CR cases (98% vs 92%, P=.14). On multivariate analysis, HPV(+) status predicted ultimate LN resolution (odds ratio, 1.4 [95% confidence interval, 1.1-1.7]; P<.01) and RC (hazard ratio, 0.3 [95% confidence interval 0.2-0.6]; P<.01). Conclusions HPV(+) LNs involute more quickly than HPV(-) LNs but undergo a more prolonged process to eventual CR beyond the time of initial assessment at 8 to 12 weeks after treatment. Post radiation neck dissection is advisable for all non-CR HPV(-)on-CR N3 HPV(+) cases, but it may be avoided for selected non-CR N2 HPV(+) cases with a significant LN involution if they can undergo continued imaging surveillance. The role of positron emission tomography for response assessment should be investigated.
机译:目的比较人乳头瘤病毒相关[HPV(+)]与人乳头瘤病毒无关[HPV(-)]头进行化学放疗/放疗后颞淋巴结消退和区域控制(RC)。颈部癌(HNC)。方法和材料回顾了2003年至2009年间所有接受放射治疗/化学放射治疗的N2-N3 HNC病例。通过对所有可用的口咽癌进行p16染色来确定人乳头瘤病毒的状态。喉/下咽癌被认为是HPV(-)。比较HPV(+)和HPV(-)HNC之间的初始放射学完全结节反应(CR)(治疗后8-12周≤1.0cm),最终LN分辨率和RC。多变量分析确定了结果预测指标。结果共鉴定出257个HPV(+)和236个HPV(-)HNC。相对于HPV(-)HNC,初始LN尺寸较大(平均2.9 cm vs 2.5 cm; P <.01),而囊状LN的比例较高(38%vs 6%,P <.01)。 。 CR为125 HPV(+)HNC(49%)和129 HPV(-)HNC(55%)(P = .18)。治疗后最大LN的平均值在HPV(+)组中为原始大小的36%,在HPV(-)组中为41%(P <.01)。在12周时,HPV(+)和HPV(-)组的精算LN分辨率相似(分别为42%和43%),但HPV(+)组的精算LN分辨率高于HPV(-)组在36周时(90%对77%,P <.01)。中位随访期为3。6年。 HPV(-)CR病例的3年RC率高于非CR病例(92%vs 63%,P <.01),但HPV(+)CR病例与非CR病例无差异(98%vs 92%,P = .14)。在多变量分析中,HPV(+)状态预测了最终的LN分辨率(赔率,1.4 [95%置信区间,1.1-1.7]; P <.01)和RC(危险比,0.3 [95%置信区间,0.2-0.6] ; P <.01)。结论HPV(+)LNs比HPV(-)LNs更快地卷入,但在治疗后8到12周的初始评估时间之外,经历了更长的过程直至最终CR。对于所有非CR HPV(-)/非CR N3 HPV(+)病例,建议行放射后颈淋巴清扫术,但如果可以,对于某些LN复卷较大的非CR N2 HPV(+)病例,可以避免这种情况接受持续的影像监视。应研究正电子发射断层扫描在反应评估中的作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号